Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Colorcon
Merck
Harvard Business School
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR SYMMETREL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Symmetrel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00627250 ↗ Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability Completed U.S. Department of Education N/A 2003-03-01 The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e. irritability) after sustaining traumatic brain injury.
NCT00627250 ↗ Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability Completed Atrium Health N/A 2003-03-01 The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e. irritability) after sustaining traumatic brain injury.
NCT00627250 ↗ Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability Completed Carolinas Healthcare System N/A 2003-03-01 The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e. irritability) after sustaining traumatic brain injury.
NCT00779324 ↗ Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study Completed Icahn School of Medicine at Mount Sinai N/A 2009-08-01 The purpose of this study is to study the effect of amantadine on irritability and aggression caused by traumatic brain injury.
NCT00779324 ↗ Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study Completed Indiana University N/A 2009-08-01 The purpose of this study is to study the effect of amantadine on irritability and aggression caused by traumatic brain injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Symmetrel

Condition Name

Condition Name for Symmetrel
Intervention Trials
Traumatic Brain Injury 4
Parkinson's Disease 2
Aggression 2
Idiopathic Parkinson's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Symmetrel
Intervention Trials
Brain Injuries, Traumatic 5
Brain Injuries 5
Wounds and Injuries 3
Parkinson Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Symmetrel

Trials by Country

Trials by Country for Symmetrel
Location Trials
United States 30
Canada 1
Denmark 1
France 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Symmetrel
Location Trials
Illinois 4
North Carolina 4
Massachusetts 4
Oregon 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Symmetrel

Clinical Trial Phase

Clinical Trial Phase for Symmetrel
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Symmetrel
Clinical Trial Phase Trials
Completed 7
Terminated 3
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Symmetrel

Sponsor Name

Sponsor Name for Symmetrel
Sponsor Trials
U.S. Department of Education 2
Atrium Health 2
Carolinas Healthcare System 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Symmetrel
Sponsor Trials
Other 23
U.S. Fed 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKinsey
Mallinckrodt
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.